A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Summary

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.

Timeline

Start

2024-12-19

Primary completion

2026-12-15

Completion

2027-06-16

Drugs

Indications